Enemac Rectal Solution Single Dose Enema 130ml

NAME
ENEMAC 16,1G / 100ML + 6G / 100ML RECTAL SOLUTION

PHARMACOTHERAPEUTIC CATEGORY
Constipation medications.

ACTIVE PRINCIPLES
Monosodium phosphate monohydrate 16.10 g; disodium phosphate heptahydrate 6 g.

EXCIPIENTS
Sodium methyl p-hydroxybenzoate; FU purified water

INDICATIONS
Constipation; bowel evacuation before radiological or other diagnostic tests.

CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity to the active substance or to any of the listed excipients; anorectal affections.

DOSAGE
It is administered rectally only. Adults: 1 bottle per day. Children over 2 years: half or a quarter of the adult dose. Do not exceed the recommended dose. Method of administration: remove the screw cap and screw the cannula included. Lubricate the latter with a few drops of medication, lie down on the left side and gently introduce it into the rectum. Squeeze the bottle to release the liquid and extract it while holding it down. Keep the liquid in a lying position, until you feel the urgent need to evacuate (about 5 minutes): it is not necessary to hold back more than 10-15 minutes.

STORAGE
Store at a temperature below 30 degrees C; do not disperse in the environment. Store in ordinary environmental conditions.

WARNINGS
In children over two years of age, the cannula should not penetrate beyond half of its length. In the cold season it is advisable to bring the product to room temperature by heating it in a bain-marie. Use in occasional administrations. Do not use in children under two years of age. The continuous use of laxatives can cause addiction or damage of various kinds. Do not use laxatives if abdominal pain, nausea and vomiting are present. If constipation is persistent, see your doctor. Prolonged use can induce a state of dehydration. The product contains sodium salts in the quantity indicated above; this should be taken into account in the case of a low-sodium diet.

INTERACTIONS
No interactions with other drugs have been reported so far.

SIDE EFFECTS
Prolonged use can induce a state of dehydration. The patient is invited to communicate to his doctor or pharmacist the onset of any undesirable effect that may appear in case of use. The reporting of suspected adverse reactions that occur after the authorization of the drug is important, as it allows continuous monitoring of the benefit / risk ratio of the drug.

PREGNANCY AND BREASTFEEDING
Use during pregnancy is not contraindicated.